Kidney Cancer | Topics

 
High-Risk Renal Cell Carcinoma: 51-Year-Old Male
April 21, 2021

Around the Practice: High-Risk Renal Cell Carcinoma

NCCN Recommends Frontline Lenvatinib/Pembrolizumab for Advanced RCC
April 09, 2021

CancerNetwork spoke with Eric Jonasch, MD, about the NCCN’s recommendation and how thee multidisciplinary approach will play a role.

Pembrolizumab Monotherapy Improves DFS in Patients With Renal Cell Carcinoma
April 08, 2021

Merck announced an interim analysis of pembrolizumab to treat RCC, finding a clinically significant improvement in disease-free survival when compared with placebo.